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bcl-w is a member of the bcl-2 gene family and was initially
characterized by Gibson et al (1996). bcl-w codes for a protein of
22 kDa apparent molecular weight. The Bcl-w protein was demon-
strated to be of similar efficacy to Bcl-xL in suppressing apoptosis
of haemopoietic cell lines, induced by a number of cytotoxic
stimuli including g-radiation, interleukin (IL)-3 withdrawal,
dexamethasone, but not CD95 ligation. Bcl-w’s role in promoting
cell survival was further illustrated by the breeding of bcl-w-defi-
cient mice (Ross et al, 1998). Male, homozygous, mutant mice
demonstrated progressive testicular degeneration and were sterile.
The studies presented in the current manuscript suggest that
expression of Bcl-w may play a role in the progression of
colorectal carcinogenesis. We have previously characterized the
differential expression of Bcl-2 and p53 in colorectal tumours
(Watson et al, 1996), and shown an inverse relationship between
Bcl-2 expression and the accumulation of p53 immunoreactivity
(indicative of p53 mutation). Bcl-2 was found to be most
frequently expressed in adenomas relative to adenocarcinomas.
Here we present results demonstrating the frequent expression of
Bcl-w in colorectal adenocarcinomas but not in adenomas, in
contrast to Bcl-2. The relationship between Bcl-w, Bcl-2 and p53
status and other clinical histopathological parameters is discussed.
MATERIALS AND METHODS
Patient samples
Samples were obtained from patients undergoing radical surgery
for colorectal cancer. Exclusion criteria for the study were: age
greater than 75 years, presence of synchronous, distant metastases
or residual tumour after surgery and previous history of neoplasm.
Pathology
Tumours were classified as follows: proximal (right) tumours –
from the caecum to the splenic flexure; distal (left) tumours – from
the splenic flexure to the end of the sigmoid; and rectal tumours.
Tumours were identified as either adenocarcinoma or mucinous
adenocarcinoma. On the basis of differentiation, tumours were
divided into three groups: well differentiated, moderately differen-
tiated and poorly differentiated, according to World Health
Organization classification (Jass and Sobin, 1989). All patients
were staged according to Dukes’ classification, as modified by
Dukes and Gabriel (Gabriel et al, 1935) and according to the
tumour–node–metastasis (TNM) classification (Hermanek and
Sobin, 1987).
Tumour ploidy
Tumour ploidy was assessed by flow cytometric determination of
DNA content. Multiple fragments of tumour were minced with a
scalpel in a citrate-buffered solution to obtain a single nuclei
suspension. The suspension of the standard cell population was
obtained by scraping of the mucosa, cut 10 cm above the
neoplasm. Both suspensions were filtered through a 50 mm nylon
mesh to remove cell clumps and the cell density adjusted to 1 ´ 106
cells ml–1. Samples were stained with propidium iodide according
to the method of Vindelov (Vindelov and Christensenn, 1990).
Samples of tumour, normal mucosa and mixed tumour and
normal epithelial cells were analysed using a FACScan flow
cytometer (Becton Dickinson) to give a single parameter
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Figure 1 Bcl-w immunoreactivity in colorectal adenocarcinomas – part I. Four pairs of normal and tumour tissue (A + B; C + D; E + F; G + H) from different
patients are shown. The epithelia of the normal mucosal samples (A, C, E and G) demonstrated no significant immunoreactivity. Tumours shown are TNM stage
I (Dukes’ A) – D and H; TNM stage II (Dukes’ B) – A; TNM stage III (Dukes’ C1) – F. Bar shown in plate A = 50 mm
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Figure 2 Bcl-w immunoreactivity in colorectal adenocarcinomas – part II. Tumour shown in A–D is an adenocarcinoma, TNM stage 3 (Dukes’ stage C1).
Plates show tumour sections incubated with anti-Bcl-w IgG (A); a non-specific goat IgG – 0.67 mg ml–1 (B); anti-Bcl-w IgG pre-incubated with antigenic peptide
(C); secondary antibody alone (D). Bar in plate C = 100 mm
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integrated fluorescence histogram. DNA ploidy was defined as the
DNA index (DI), i.e. the ratio between the mean channel number of
the G0/G1 peak of the tumour cells and that of the normal epithelial
cells. Tumours with DI = 1 were defined as diploid and tumours
with lower or higher values were considered aneuploid. Cases with
DI value between 1.9 and 2.1 were classified as tetraploid tumours,
if this peak represented more than 20% of the cell population.
Analysis of the S phase fraction (SPF) was performed using
Multicycle (Phoenix) and CellFit software (Becton Dickinson),
using the Sum of Broadened Rectangles model for diploid samples
and the polynomial model for aneuploid cases.
Antibodies
Primary antibodies
Goat anti-Bcl-w IgG (n19: sc6171) was obtained from Santa Cruz
Biotechnology (via Autogen Bioclear, Devizes, UK). Mouse anti-
Bcl-2 IgG (clone 124: M0887) and mouse anti-p53 IgG (DOH7:
M7001) were obtained from Dako (High Wycombe, UK).
Secondary antibodies
Rabbit anti-goat, biotin-conjugated IgG was obtained from Vector
Labs (Peterborough, UK). Goat anti-mouse, biotin-conjugated IgG
was obtained from Pierce and Warriner (Chester, UK).
Immunohistochemistry
Immunohistochemistry was carried out as previously described
(Wilson and Potten, 1996). Briefly, sections were dewaxed
in xylene and transferred to absolute alcohol. Endogenous
peroxidase activity was blocked by incubation of sections in 3%
H2O2/methanol. Sections were then rehydrated through a graded
series of alcohols, prior to microwave-based antigen retrieval.
Sections were incubated in pre-block solution (10%, 0.2 mm
filtered serum in phosphate-buffered saline (PBS)-goat serum for
anti-p53 and -Bcl-2; rabbit serum for anti-Bcl-w). Incubation with
primary antibodies (diluted in fresh pre-block solution) was
performed overnight, at 4°C in an humidified chamber. Anti-Bcl-w
IgG was used at a concentration of 0.67 mg ml–1; anti-Bcl-2 IgG
was used at a concentration of 2 mg ml–1 and anti-p53 IgG was
used at a concentration of 4 mg ml–1. After a brief wash with
TBS–Tween, sections were incubated with biotinylated secondary
antibody (1:200 dilution), for 1 h at room temperature. Vector
ABC reagents were used, in accordance with  manufacturers’
instructions, to amplify the immunoreactivity. Detection of
immunoreactivity was performed using 3¢3¢-diaminobenzidine
(DAB) as a chromogen. Slides were counterstained with thionine
blue, prior to mounting with XAM permanent mount.
Western blotting
Tumour lysates were prepared by homogenizing pieces of tumour
tissue (previously frozen in liquid nitrogen and stored at –80°C) in
Laemlli buffer, in the presence of protease inhibitors (CompleteTM,
Boehringer Mannheim). The protein concentration of the samples
was determined using BCA assay reagents from Pierce (Pierce and
Warriner). Forty micrograms of protein (in 30 ml) was loaded onto
10% Bis–Tris Nupage gels (Novex, Oxford, UK) and run at 200 V
for 35 min using MES (2-[N-morpholino] ethane sulphonic acid)
running buffer (Novex). Proteins were transferred on to Hybond
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Figure 3 (A). Western blot of Bcl-w immunoreactivity. Panels show membranes incubated in the absence (left), or presence (right), of primary antibody.
Molecular size markers are indicated. Lanes A, B, C, D, E and F are samples prepared from six different adenocarcinomas (A and F are Dukes’ A; B and D are
Dukes’ B; C and E and Dukes’ C1). It may be noted that the secondary antibody used for Western analysis shows immunoreactivity against a c. 50 kDa size
protein. Other secondary antibodies were tested and all showed similar immunoreactivity against a c. 50 kDa protein. (B) Immunoblots of sample F from Figure
2A, incubated with anti-Bcl-w IgG (1), secondary antibody alone (2) or with anti-Bcl-w IgG pre-incubated with excess antigenic peptide (3)ECL (Amersham, UK), using Tris Glycine Transfer Buffer
(Novex). After transfer, the membrane was washed briefly in TBS,
prior to overnight incubation in 4% dried milk/1% rabbit serum in
TBS–Tween 20 (0.1%), at 4°C. The next day the membrane was
incubated with anti-Bcl-w antibody (0.4 mg ml–1 dilution) in 4%
dried milk/1% rabbit serum in TBS–Tween 20 (0.1%), for 2.5 h on
an orbital shaking table. The membrane was then washed (for
2 min) twice with TBS–Tween 20 (0.1%), prior to incubation with
rabbit anti-goat IgG-horseradish peroxidase (human adsorbed:
Santa Cruz Biotechnology/Autogen Bioclear) at 1/200 dilution in
4% milk/1% human serum in TBS–Tween (0.1%) for 1 h. The
membrane was subsequently washed 4 times (12 min each wash)
in TBS–Tween 20 (0.1%). Immunodetection was performed using
ECL-plus reagents and ECL-hyperfilm (Amersham). To block
specific immunoreactivity, primary antibody was also pre-incu-
bated with a tenfold excess of Bcl-w peptide blocking solution
(Santa Cruz/Autogen Bioclear), overnight at 4°C.
Tumour scoring
Tumour sections were viewed by two independent observers. A
consensus score out of three was given for both the intensity of
immunoreactivity (INT) observed and the proportion of epithelial
cells within the tumour that showed immunoreactivity (PROP).
The product of the two scores was used to give a final score for the
degree of immunoreactivity (total score: TS). Tumours were
scored without prior knowledge of tumour histopathology.
Statistics
Data were analysed using SPSS for Windows. Data were
compared using a non-parametric Kruskal–Wallis test for analysis
of variance, and a Mann–Whitney test was used to assess the
difference between individual data sets. The level of significance
was determined at P ≤ 0.05.
RESULTS
Bcl-w expression
Colorectal adenocarcinomas
Of the 75 colorectal adenocarcinomas examined, 69 (92%)
demonstrated Bcl-w immunoreactivity. Examples of staining
observed in tumours from four different patient samples are shown
in Figure 1. Also shown are normal mucosa samples from the same
patients, taken from sites 10 cm from the tumour; these showed no
significant Bcl-w immunoreactivity. The Bcl-w staining observed
in the tumour samples was cytoplasmic in location and could be
blocked by pre-incubation of antibody with an excess of antigenic
peptide. In addition, no significant immunoreactivity was
observed when tissue sections were incubated with non-specific
goat immunoglobulin, at an equivalent protein concentration to the
primary antibody (Figure 2).
By Western blot, a band of c.20 kDa could be detected in six out
of six tumour samples examined (Figure 3A), which is in close
agreement with the molecular weight of 22 kDa, previously
Bcl-w in colorectal adenocarcinoma 181
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Figure 4 Bcl-w expression in adenomas. Three different colorectal adenomas are shown. Adenoma 1 (A and D) and adenoma 2 (B and E) were incubated
with anti-Bcl-w IgG (A and B) and n/s goat IgG (D and E). Adenoma 2 was the only adenoma to show significant immunoreactivity. Adenoma 3 was incubated
with either anti-Bcl-2 IgG (C) or anti-Bcl-w IgG (D). The bar in plate D = 50 mmreported by Gibson et al (1996). The appearance of this 20 kDa
band could be blocked by the pre-incubation of anti-Bcl-w IgG
with an excess of antigenic peptide (Figure 3B).
Colorectal adenomas
In comparison to the adenocarcinomas, only one of 17 adenomas
demonstrated Bcl-w immunoreactivity, whereas six out of nine
adenomas tested were positive for Bcl-2 expression (see Figure 4).
Adenocarcinomas from other epithelial tissues
As we had observed a high frequency of Bcl-w immunoreactivity
in the colorectal adenocarcinomas, other adenocarcinomas from
different epithelial tissues were examined. Tumour specimens
were obtained for breast, cervix and stomach. Zero out of eight
breast tumours and zero out of 12 cervical tumours examined were
positive for Bcl-w and only one out of 12 stomach tumour demon-
strated immunoreactivity (Figure 5).
Relationship between Bcl-w expression and other
factors (Table 1)
Sex
There were 33 male patients (mean age (± s.e.m.) 63.3 ± 1.7)
and 42 female patients (mean age 63.1 ± 1.4) included in the study.
Twenty-nine out of 33 (88%) of tumours from male patients, and
40/42 (95%) of tumours from female patients demonstrated some
degree of Bcl-w expression. Kruskal–Wallis/Mann–Whitney
analysis revealed that the proportion of cells demonstrating
expression of Bcl-w (PROP: see Materials and Methods) was
significantly greater in tumours from female patients (at P =
0.016). This difference was not reflected in any difference in the
intensity (INT) of Bcl-w immunoreactivity, or the total score (TS;
where TS = PROP score ´ INT score) for Bcl-w immunoreactivity,
between tumours from male and female patients.
Site of tumour
Tumours were classified, according to their location within the
large bowel. The current data set included 24 right-sided, 23 left-
sided and 28 rectal tumours. Kruskal–Wallis analysis showed there
to be no relationship between Bcl-w expression and site of tumour.
Tumour histopathology
TNM stage By TNM staging criteria, there were 16 stage I, 35
stage II and 24 stage III tumours (one not determined).
Kruskal–Wallis analysis demonstrated a relationship between
TNM stage and Bcl-w staining intensity (P = 0.022) and Bcl-w
total score (P = 0.029). Mann–Whitney analysis showed that both
Bcl-w intensity and Bcl-w total score were significantly greater in
stage III tumours relative to stage II tumours, both at P = 0.009.
Classification of tumours according to Dukes’ staging showed a
similar relationship to Bcl-w expression (data not shown).
Histotype Tumour histotype was defined as being adenocarci-
noma (n = 56), adenocarcinoma with mucinous expression (less
than 50%: n = 9) and mucinous adenocarcinoma (n = 10). There
was a significant difference (P = 0.046) between the Bcl-w total
scores of tumours of different histotype. Mann–Whitney analysis
demonstrated that the Bcl-w total scores for mucinous adenocarci-
nomas were significantly less than those for adenocarcinomas and
adenocarcinomas with mucinous expression (less than 50%), at
P = 0.023 and P = 0.035 respectively. This set of tumours was
further analysed in relation to p53 status (see p53 and bcl-2
below).
Grade of differentiation Tumours were graded as either well
(n = 3), moderately (n = 55) or poorly differentiated (n = 6); one
adenocarcinoma was not classified. Mucinous adenocarcinomas
(n = 10) were graded as unclassified. Within the classified groups,
there was no significant difference in Bcl-w status. The unclassi-
fied (mucinous) tumours had significantly lower Bcl-w INT scores
(P = 0.007) and Bcl-w total scores (P = 0.017) than the moderately
differentiated group of tumours.
Tumour ploidy
Although increased ploidy was associated with increased Bcl-w
expression, analysis of Bcl-w status in relation to tumour ploidy
revealed no significant relationship between the two.
Node involvement
There were 51 node-negative tumours (group N1 – see Table 1)
and 24 tumours with varying degrees of node involvement (group
N5). Kruskal–Wallis/Mann–Whitney analysis showed that Bcl-w
expression was significantly greater in the node-positive group.
This was the case for the proportion of tumour epithelial cells
showing Bcl-w immunoreactivity (P = 0.033), the intensity of
Bcl-w immunoreactivity (P = 0.022) and the Bcl-w total score
(P = 0.02).
Bcl-2 and p53
p53 and Bcl-2 status were also established for the colorectal
adenocarcinomas examined. p53 expression was observed with a
182 JW Wilson et al
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Table 1 Relationship between Bcl-w immunoreactivity and tumour
pathology
Bcl-w INT score Bcl-w PROP score Bcl-w total score
Sex (Mean values ± standard error)
Male (n = 33) 1.5 ± 0.2 2.1 ± 0.2 3.6 ± 0.5
Female (n = 42) 1.5 ± 0.1 2.5 ± 0.1 4.3 ± 0.4
Site
Right (n = 24) 1.5 ± 0.2 2.2 ± 0.2 3.8 ± 0.6
Left (n = 23) 1.5 ± 0.2 2.3 ± 24   ± 0.7
Rectum (n = 28) 1.5 ± 0.2 2.3 ± 0.2 4 ± 0.5
TNM stage (1 N.D.)
I (n = 16) 1.7 ± 0.2 2.4 ± 0.2 4.5 ± 0.8
II (n = 34) 1.2 ± 0.1 2.1 ± 0.2 3.1 ± 0.4
III (n = 24) 1.9 ± 0.2 2.7 ± 0.1 5 ± 0.5
Tumour ploidy (2 N.D.)
Diploid (n = 28) 1.4 ± 0.2 2.1 ± 0.2 3.8 ± 0.6
Near diploid (n = 11) 1.3 ± 0.2 2.2 ± 0.3 3.2 ± 0.8
Tetraploid (n = 8) 1.7 ± 0.3 2.8 ± 0.2 4.8 ± 0.9
Aneuploid (n = 21) 1.5 ± 0.2 2.4 ± 0.1 3.7 ± 0.6
Polyploid (n = 5) 2.1 ± 0.3 2.4 ± 0.4 5.5 ± 1.4
Node involvement
1 (zero, n = 51) 1.3 ± 0.12 2.1 ± 0.1 3.5 ± 0.4
2 (N1, n = 17) 2 ± 0.2 2.7 ± 0.1 5.4 ± 0.6
3 (N2, n = 5) 1.8 ± 0.4 2.6 ± 0.2 4.9 ± 1.3
4 (N3, n = 2) 0.8 3 2.3
5 (Any: N1+N2+N3,
n = 24) 1.9 ± 0.2 2.7 ± 0.1 5 ± 0.5
Histotype
Adenocarcinoma a
n = 56) 1.6 ± 1 2.4 ± 0.1 4.2 ± 0.4
Mucinous expression
< 50% (n = 9) 1.8 ± 0.3 2.4 ± 0.2 4.9 ± 1
Mucinous (n = 10) 0.9 ± 0.2 1.9 ± 0.3 2 ± 0.5Bcl-w in colorectal adenocarcinoma 183
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similar profile to that of Bcl-w and was expressed in 76% of the
adenocarcinomas. Bcl-2 was observed in only 41% of adenocarci-
nomas, compared to its expression in 67% of adenomas.
Spearman’s correlation coefficients were calculated to determine
the relationship, if any, between Bcl-w status and p53 and Bcl-2
status. This revealed significant, positive correlations between the
proportion of p53-immunoreactive tumour epithelial cells and (a),
the proportion of Bcl-w immunoreactive tumour epithelial cells
(r = 0.344, P = 0.002); (b), the intensity of Bcl-w staining
(r = 0.296, P = 0.01); and (c), the total score for Bcl-w immuno-
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Figure 5 Bcl-w expression in other adenocarcinomas. Breast (A–C), stomach (D–F) and cervix (G–I) adenocarcinomas. Bcl-w immunoreactivity was observed
only in one stomach tumour (F)184 JW Wilson et al
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reactivity (r = 0.327, P = 0.004). There was also a significant, posi-
tive correlation between the total score for p53 immunoreactivity
and the total score for Bcl-w immunoreactivity (r = 0.241,
P = 0.037).
Some adenocarcinoma samples contained adjacent adenoma-
tous tissue. These samples allowed excellent visualization of the
contrast between the positively-stained adenocarcinoma tissue and
the adenomatous tissue, which was negative for both Bcl-w and
p53 immunoreactivity (Figure 5). The low level of Bcl-w expres-
sion in mucinous adenocarcinomas (as mentioned above), was
correlated with a low level of p53 expression in these tumours,
with Bcl-w PROP score showing strong, positive correlation with
the p53 PROP score (r = 0.787; P = 0.007) and p53 TS (r = 0.765;
P = 0.01).
Kruskal–Wallis analysis revealed that the proportion of tumour
epithelial cells demonstrating p53 expression was significantly
influenced by the site of the tumour (P = 0.048). Mann–Whitney
analysis showed that the proportion of tumour epithelial cells
expressing p53 was greater in left-sided tumours compared to
right-sided tumours (P = 0.017). No significant difference was
observed between right-sided and rectal tumours (P = 0.063), and
left-sided and rectal tumours (P = 0.64)
Like Bcl-w, Bcl-2 expression was also related to TNM stage.
Bcl-2 intensity was shown to be significantly different between the
stages, by Kruskal–Wallis analysis (P = 0.021). Mann–Whitney
analysis showed that the intensity of Bcl-2 immunoreactivity was
significantly greater in stage I tumours than in either stage II
(P = 0.01), or stage III (P = 0.038) tumours. However, no signifi-
cant difference was observed in Bcl-2 total score between the
different groups.
Bcl-w as a prognostic indicator?
We have been following up this group of patients for evidence of
relapse, metastatic disease and mortality. At the time of writing,
follow-up information was available for 63 of the 75 cases exam-
ined. Of the 63 cases with known status, nine patients had died:
four from metastatic disease and five from local relapse. Amongst
the group of surviving patients, 46 were free from disease, five had
experienced metastases and three had local relapse. The mean
follow-up period for patients included in this study is currently
only 24 months. This is too short a period to allow proper evalua-
tion of the relation between Bcl-w expression and future incidence
of metastatic disease, relapse and death, for a disease such as
colorectal cancer. However, we will continue follow-up for these
patients in order to assess this.
CONCLUSIONS
The current studies have demonstrated that Bcl-w expression was
observed in greater than 90% of colorectal adenocarcinomas
examined. Bcl-w was not observed in any of the normal mucosal
samples studied and in only one of 17 colorectal adenomas. It was
interesting to observe that adenocarcinomas from other epithelial
tissues did not express Bcl-w.
Bcl-w appears to have an opposite pattern of expression to
Bcl-2, which previously has been shown to be more frequently
expressed in colorectal adenomas relative to adenocarcinomas
(Watson et al, 1996). However, there was no significant, inverse
correlation between Bcl-2 status and Bcl-w status in the
adenocarcinomas examined. p53 expression did correlate well
with Bcl-w expression. There were also data to suggest that
increased Bcl-w expression could be related to tumour progres-
sion, with TNM stage III tumours demonstrating higher Bcl-w
expression than stage II tumours. The reduced expression of
Bcl-w in mucinous adenocarcinomas relative to the other tumours
was a very interesting finding. As mentioned in the results, this
was correlated with a low level of p53 expression. In addition,
these tumours were predominantly right-sided (7/10), of TNM
stage II (Dukes’ B) (8/10), and showed no evidence of node
involvement (9/10).
More data are clearly required to establish if Bcl-w status can be
related in any way to the chemo- or radio-sensitivity of the tumour
A
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Figure 6 Contrasting Bcl-2 (A) Bcl-w (B) and p53 (C) expression in a TNM
stage 2 (Dukes’ B) adenocarcinoma with adjacent adenomatous tissue (left).
The adenocarcinoma shows strong staining for p53 and Bcl-w in contrast to
the adjacent adenomatous tissue. The bar in plate A = 100 mmBcl-w in colorectal adenocarcinoma 185
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cells, clinical outcome, and patient survival. As Bcl-w has been
identified as a potent suppressor of apoptosis (Gibson et al, 1996),
it could confer significant survival advantage to tumour. The
precise mechanism whereby Bcl-w expression is up-regulated also
remains to be established. No germline mutations within the bcl-w
gene have been reported (Gibson et al, 1996). Gibson et al (1996)
demonstrated that the bcl-w gene was located on chromosome 14,
at band q11. Although lymphoid leukaemias frequently show
chromosomal aberrations at 14q11, Gibson et al thought that it
would be hard to define the functional role of Bcl-w in these
malignancies, due to the close linkage of the bcl-w gene and the
tcra locus. The 14q11 region has been reported to show alteration
in colorectal cancer cell lines by Gagos et al (1995). However,
there are no current data demonstrating that a chromosomal
rearrangement results in increased bcl-w expression. The clono-
genic expansion of Bcl-2-expressing stem cells, the putative site of
initial transformation events in colorectal cancer, is thought to
explain the high expression of Bcl-2 in adenomas. Bcl-w on the
other hand is not expressed in the normal mucosa, at least not at
levels which allow detection.
Several questions need to be addressed by further studies. Is the
dysregulation of Bcl-w expression a common step in the progres-
sion from adenoma to adenocarcinoma in colorectal cancer? Also,
why is dysregulated Bcl-w expression specific to colorectal
tumours, within the group of epithelial tumours so far examined?
We are initiating further studies to assess the importance of Bcl-w
in determining the apoptotic sensitivity of colorectal tumour cells
and will be following up patients to more thoroughly assess the
relationship between Bcl-w expression, disease progression and
patient survival.
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Note addied in proof
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